Next Science Limited (ASX:NXS)
Next Science Limited (ASX:NXS) is a medical technology company focused on the development and ongoing commercialisation of its proprietary Xbio technology designed to reduce the impact of biofilm-based infections in human health.
Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria.
Next Science owns the patent protected intellectual property relating to its Xbio technology.
The Company was established in 2012 and is headquartered in Sydney, Australia, with a research and development centre in Florida, USA.